# Rat HER2 / ErbB2 Protein (His Tag)

Catalog Number: 80079-R08H



## **General Information**

### Gene Name Synonym:

ERBB2

#### **Protein Construction:**

A DNA sequence encoding the rat ErbB2 (AAH61863.1) extracellular domain (Met 4-Thr 656) was expressed, fused with a polyhistidine tag at the C-terminus.

Source: Ra

Expression Host: HEK293 Cells

**QC** Testing

Purity: > 95 % as determined by SDS-PAGE

**Endotoxin:** 

< 1.0 EU per µg of the protein as determined by the LAL method

Stability:

Samples are stable for up to twelve months from date of receipt  $\,$  at -70  $\,$   $^{\circ}$ C

Predicted N terminal: Thr 26

### **Molecular Mass:**

The recombinant rat ErbB2 comprises 642 amino acids and predicts a molecular mass of 71.3 kDa. The apparent molecular mass of the rat ErbB2 is approximately 110 kDa in SDS-PAGE under reducing conditions due to glycosylation.

### Formulation:

Lyophilized from sterile PBS, pH 7.4

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

## **Usage Guide**


### Storage:

Avoid repeated freeze-thaw cycles.

### Reconstitution:

Detailed reconstitution instructions are sent along with the products.

#### SDS-PAGE:



# **Protein Description**

Epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein, and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.

### References

3.Krawczyk N, et al. (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10): 4019-24.

Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

For US Customer: Fax: 267-657-0217 • Tel: 215-583-7898

Global Customer: Fax :+86-10-5862-8288 

■ Tel:+86-400-890-9989 

■ http://www.sinobiological.com